Life-extending peptides are likely not around the corner
Excitement in the longevity space over peptides comes with the caveat that many claims about their life-extending potential are incomplete…
Excitement in the longevity space over peptides comes with the caveat that many claims about their life-extending potential are incomplete…
The entry of prediction markets into the pharmaceutical sector means new pathways to access money, but also brings new risks.…
Publicly traded drug developers have been exposed to insider trading on their stocks for decades, but with the introduction of…
Despite the region’s reputation as a thriving hub of innovation, Nordic biotechs are having a hard time funding the jump…
A closer look at the numbers that paint China as accelerating towards global biopharma dominance and you will find indications…
Experts say we can thank an improved understanding of the biology behind central nervous system (CNS) diseases for the resurgence…
The FDA’s acceptance of several untested peptides for human use has left one drug innovator calling for a greater clarity…
The US policy of Most Favoured Nation (MFN) pricing has raised uncertainty in European markets reluctant to raise drug prices…
Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier’s head of business development outlines how one of France’s…
June was a busy month for Pharmaceutical Technology’s editorial team, with journalists attending several key conferences with reach across the…